Navigation Links
Rivaroxaban in Medical News

New Anticoagulant Pill Works Well in Trial

... 17 (HealthDay News) -- The new anti-clotting pill rivaroxaban (Xarelto) lowers the risk of stroke, heart attack ...suffer from unstable angina, a new trial shows. rivaroxaban is a pill that blocks factor Xa, which is involved... these observations, a phase III study of low-dose rivaroxaban as adjunctive therapy in these patients is underwa...

FDA Panel Backs New Anti-Clotting Drug

... rivaroxaban could replace heparin after hip- or knee-replaceme...e benefits of the experimental blood-thinning drug rivaroxaban outweigh its risks, a U.S. Food and Drug Administration advisory panel said Thursday. rivaroxaban (Xarelto) could be one of the long-sought alternat...

Research highlights new approaches to prevent blood clots

...rates of secondary endpoints. Once-Daily Oral rivaroxaban Compared With Subcutaneous Enoxaparin Every 12 Hou...ous research that demonstrated that post-operative rivaroxaban was more effective than pre-operative enoxaparin i... were randomized to receive either once-daily oral rivaroxaban (10 mg) starting six to eight hours after surgery ...

Phase II Trial of Experimental Anti-Coagulant Reports Safety and Outcomes Data

...ed on a study of a new oral anti-clotting agent -- rivaroxaban -- designed to identify doses that would be safe t... Earlier studies had shown the experimental drug rivaroxaban effective at keeping blood clots from forming in t...ndomized to twice a day doses of 2.5 mg or 5 mg of rivaroxaban for six months is expected to begin in December 20...

Speed Not Always of the Essence With Heart Cases in ER

...ble angina). The study was the first to look at the effects of the drug in the arteries. Existing drugs target the platelets in the bloodstream. rivaroxaban targets a different part of the clotting process, called Factor X, said principal investigator Dr. Michael Gibson, chief of clinical research in cardi...

Oral Drug Helps Prevent Clotting After Hip Replacement

... Daily dose of rivaroxaban cut risk of venous thromboembolism, study finds ... (HealthDay News) -- Extended use of the oral drug rivaroxaban helps prevent potentially fatal blood clots after ...nstitute compared the new oral antithrombotic drug rivaroxaban (Xarelto) with enoxaparin in the treatment of hip ...

Rivaroxaban phase III pivotal data presented at EFORT annual meeting

...ent (TKR) surgery. The head-to-head study compared rivaroxaban with the U.S.-approved dosing regimen for enoxapar...ociations of Orthopaedics & Traumatology (EFORT). rivaroxaban is being jointly developed by Johnson & Johnson Ph...ayer HealthCare AG. The RECORD4 data show that rivaroxaban (10mg once-daily) provided TKR surgery patients a ...

Research Highlights New Approaches to Management of Blood Clotting and Bleeding Disorders

...red dose of an oral, direct Factor Xa inhibitor -- rivaroxaban -- for extended prevention of blood clotting after... III trial studied the efficacy and safety of oral rivaroxaban in comparison to subcutaneous enoxaparin to preven...l of 4,541 randomized patients who either received rivaroxaban 10 mg beginning six to eight hours after surgery a...
Rivaroxaban in Medical Technology

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

GENEVA--(BUSINESS WIRE)--Jul 8, 2007 - Late-breaking Phase III clinical trial data presented today at the XXI International Society on Thrombosis and Haemostasis (ISTH) Congress demonstrate that once-daily rivaroxaban achieved superior efficacy in the prevention of venous thromboembolism (VTE) in p...

Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery

Rivaroxaban, a New Oral, Once-Daily Direct Factor Xa Inhibitor, Shows a Significant Reduction in Deep Vein Thrombosis and Pulmonary Embolism Compared with Enoxaparin with Similarly Low Bleeding Rates GENEVA, July 8, 2007 - Late-breaking Phase III clinical trial data presented today at the XXI In...

Research Highlights New Approaches to Prevent Blood Clots in Several High-Risk Patient Populations Including Largest Study Ever to Examine Use of Blood-Thinning Medication in Patients With Cancer

... of secondary endpoints. Once-Daily Oral rivaroxaban Com p ared With Subcutaneous Enoxaparin Ev...ous research that demonstrated that post-operative rivaroxaban was more effective than pre-operative enoxaparin i... were randomized to receive either once-daily oral rivaroxaban (10 mg) starting six to eight hours after surgery ...
Other Tags
(Date:4/21/2015)... 2015 The report “Sinusitis ... analysis on the therapeutic development for Sinusitis. ... new targets and MOAs to produce first-in-class ... is available @ http://www.rnrmarketresearch.com/sinusitis-pipeline-review-h1-2015-market-report.html . ... involved in the therapeutic development for Sinusitis ...
(Date:4/21/2015)... April 21, 2015 Wireless Analytics, ... has been recognized by the Boston Business Journal as ... ranking was announced at a recent event celebrating the ... of the fastest-growing private companies in Massachusetts. , Wireless ... the state that recorded the fastest revenue growth from ...
(Date:4/21/2015)... April 21, 2015 QuickMedical, a ... and supplies, now represents Schiller America's ... ECGs, Stress Tests, and Vital Signs Monitors, among ... Switzerland, is a global leader in the development ... are developed in close cooperation with the world's ...
(Date:4/21/2015)... San Diego, CA (PRWEB) April 21, 2015 ... Deconstructed PACS® strategy , Visage Imaging ... Ltd. (ASX: PME), has signed a seven-year contract ... health system in Northern Florida. The deal furthers ... the university/academic hospital space, a key area of the ...
(Date:4/21/2015)... Baltimore, Maryland (PRWEB) April 21, 2015 ... air, according to the U.S. Environmental Protection Agency (EPA). ... UV rays and cigarette smoke increase the level of ... help the body eliminate these harmful toxins is to ... superfood, broccoli boasts the highest level of glucoraphanin – ...
Breaking Medicine News(10 mins):Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Sinusitis Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2Health News:QuickMedical Launches New Product Line: Schiller America 2Health News:QuickMedical Launches New Product Line: Schiller America 3Health News:Visage Imaging Signs University of Florida Health 2Health News:Visage Imaging Signs University of Florida Health 3Health News:Visage Imaging Signs University of Florida Health 4Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 2Health News:New Survey Shows Americans Are Cooking the Health Out of Broccoli 3
(Date:4/14/2015)... , April 14, 2015  HYPR Corp. ... Online (FIDO ® ) Alliance tm , an ... FIDO members commit to share technology and collaborate ... that are interoperable, more secure and private, and ... biometric identity verification that protects sensitive user information ...
(Date:4/10/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ) ... Profiles - NEC" report to their offering. ... continue to supply a range of IT security management ... focus on the development of a Big Data and ... the Asia-Pacific region is a ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NEC Security Competitive Profile 2015 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
Other Contents